Complete financial analysis of Capstone Therapeutics Corp. (CAPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capstone Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Axion Ventures Inc. (AXNVF) Income Statement Analysis – Financial Results
- Gladstone Investment Corporation (GAINM) Income Statement Analysis – Financial Results
- Hariom Pipe Industries Limited (HARIOMPIPE.BO) Income Statement Analysis – Financial Results
- Model N, Inc. (MODN) Income Statement Analysis – Financial Results
- Prajay Engineers Syndicate Limited (PRAENG.NS) Income Statement Analysis – Financial Results
Capstone Therapeutics Corp. (CAPS)
About Capstone Therapeutics Corp.
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.35M | 61.56M | 66.74M | 45.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.74M | 45.03M | 50.43M | 34.52M | 39.00K | 157.00K | 205.00K | 179.00K | 157.00K | 0.00 | 0.00 |
| Gross Profit | 9.61M | 16.53M | 16.32M | 10.94M | -39.00K | -157.00K | -205.00K | -179.00K | -157.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 19.88% | 26.85% | 24.45% | 24.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37M | 1.04M | 1.04M | 1.18M | 3.07M | 3.12M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 762.00K | 554.00K | 641.00K | 543.00K | 1.76M | 1.45M | 1.09M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -39.00K | -157.00K | -205.00K | -179.00K | -157.00K | 0.00 | 82.00K |
| SG&A | 10.87M | 12.54M | 11.68M | 8.54M | 723.00K | 397.00K | 436.00K | 364.00K | 1.60M | 1.45M | 1.17M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.87M | 12.54M | 11.68M | 8.54M | 723.00K | 397.00K | 1.48M | 1.41M | 2.78M | 4.58M | 4.14M |
| Cost & Expenses | 49.61M | 57.57M | 62.11M | 43.06M | 762.00K | 554.00K | 1.68M | 1.58M | 2.94M | 4.58M | 4.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 156.00K | 70.00K | 81.00K | 4.00K | 17.00K | 6.00K |
| Interest Expense | 1.53M | 895.00K | 1.06M | 710.00K | 261.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 306.00K | 241.00K | 386.00K | 245.00K | 39.00K | 157.00K | 205.00K | 179.00K | 157.00K | 160.00K | 173.00K |
| EBITDA | -1.75M | 4.23M | 5.02M | 2.64M | -723.00K | -397.00K | -1.48M | -1.41M | -2.78M | -4.36M | -4.12M |
| EBITDA Ratio | -3.62% | 6.88% | 7.52% | 5.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.26M | 3.99M | 4.64M | 2.40M | -762.00K | -554.00K | -1.68M | -1.58M | -2.94M | -4.52M | -4.29M |
| Operating Income Ratio | -2.60% | 6.49% | 6.95% | 5.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.33M | -895.00K | -279.00K | -710.00K | -261.00K | -248.00K | -111.00K | -81.00K | -24.00K | -43.00K | 158.00K |
| Income Before Tax | -3.59M | 3.10M | 4.36M | 1.69M | -1.02M | -802.00K | -1.79M | -1.67M | -2.96M | -4.57M | -4.14M |
| Income Before Tax Ratio | -7.41% | 5.03% | 6.53% | 3.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 234.00K | 783.00K | 436.00K | -8.49M | -24.00K | -49.00K | -36.00K | -56.00K | -192.00K | 400.00K | 21.00K |
| Net Income | -3.82M | 2.32M | 3.92M | 10.46M | -2.07M | -380.00K | -1.76M | -663.00K | -2.77M | -4.17M | -3.92M |
| Net Income Ratio | -7.90% | 3.76% | 5.87% | 23.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -36.39 | 14.69 | 49.46 | 107.60 | -38.12 | -6.99 | -37.20 | -16.22 | -67.78 | -101.92 | -95.90 |
| EPS Diluted | -36.39 | 14.69 | 49.46 | 107.60 | -38.12 | -6.99 | -37.20 | -16.22 | -67.78 | -101.92 | -95.90 |
| Weighted Avg Shares Out | 157.61K | 157.61K | 79.28K | 79.28K | 54.38K | 54.38K | 47.17K | 40.89K | 40.89K | 40.89K | 40.89K |
| Weighted Avg Shares Out (Dil) | 157.61K | 157.61K | 79.28K | 79.28K | 54.38K | 54.38K | 47.17K | 40.89K | 40.89K | 40.89K | 40.89K |
JULY HARVARD CAPS / HARRIS POLL: HARRIS RESETS RACE TO PRE-DEBATE LEVELS FOLLOWING HER ENTRANCE; TRUMP HOLDS LEAD
79% OF VOTERS APPROVE OF BIDEN'S DECISION TO STEP DOWN KAMALA HARRIS ENJOYS A 9 POINT JUMP IN FAVORABILITY FOLLOWING HER ANOINTMENT AS THE FRONTRUNNER DEMOCRATIC CANDIDATE TRUMP LEADS HARRIS BY 3 POINTS, DOWN FROM HIS JUNE 7 POINT LEAD...
Capstone Holding Corp. Reinstates Tax Benefit Plan
ALSIP, IL / ACCESSWIRE / May 3, 2024 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company") On May 1, 2024, the Board of Directors (the "Board") of Capstone Holding Corp. (the "Company") authorized and declared a dividend distribution of one right...
Capstone Holding Corp. Announces Change in Board of Directors
ALSIP, IL / ACCESSWIRE / December 29, 2023 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company") Effective December 28, 2023, the Company accepted the resignations of Frederic R. Feldman, PhD, and Elwood D.
Capstone Holding Corp. Announces Change of Equity Ownership in Diamond Products Holding, LLC
ALSIP, IL / ACCESSWIRE / November 21, 2023 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company") Effective November 16, 2023, the Company reached agreement to revise its accounting treatment for Capstone Beta, LLC's note investment in Diamond Products Holdings, LLC ("DPH")...
Capstone Holding Corp. Announces CFO Change
ALSIP, IL / ACCESSWIRE / August 28, 2023 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company") Effective August 25, 2023, Omar Rabbani resigned in good standing as Chief Financial Officer of the Company. Edward Schultz, formerly Director of Financial Reporting at...
CAPS LAUNCHES EARTH DAY 2023 CAMPAIGN: SUSTAINABILITY DEPENDS ON US!
VENTURA, Calif., April 22, 2023 /PRNewswire/ — The nonprofit group Californians for Population Stabilization (CAPS), has released an Earth Day callout campaign to implore the public to recognize what sustainability requires on this Earth Day. EARTH DAY 2023: SUSTAINABILITY DEPENDS...
Executive Network Partnering Corporation Announces Pricing of Upsized $360 Million Initial Public Offering
NEW YORK--(BUSINESS WIRE)--Executive Network Partnering Corporation (the “Company”), a company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar partnering transaction with one or more businesses, today announced the pricing of...
FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that
Source: https://incomestatements.info
Category: Stock Reports